MP24-15 MR/US FUSION TARGETED BIOPSY FAILED TO DETECT PROSTATE CANCER: ROLE OF CONFIRMMDX® AS AN ADJUNCT

Abstract

INTRODUCTION AND OBJECTIVES:Negative prostate biopsies occur in up to 40% of cases following MR/US fusion targeted biopsy (TB) with concurrent systematic biopsy (SB) for PIRADS score ≥3 after at least one prior negative 12-core SB. Was the inability to detect prostate cancer (PCa) due to targeting error, inadequate sampling, or did the radiologist overcall the MRI lesion as positive? This perplexing situation leads to clinical uncertainty as to whether repeating another MR/US fusion biopsy session would be beneficial. In this study, we sought to determine whether ConfirmMDx®, a validated DNA methylation field effect assay, would be clinically useful if applied to TB + SB cores with benign pathology.METHODS:In a retrospectively maintained database, we identified 142 consecutive patients who underwent MR/US fusion TB + SB for PIRADS ≥3 following at least one negative SB session. Multiparametric MRI was performed using a 3-Tesla scanner and scored using PI-RADS Version 2. Among the 142 patients who underwent...